Ingevity Corp (NGVT)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NYSE
Market Cap: $2.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ingevity Corp (NGVT) Financials: Revenue, Profit and Cash Flow
Ingevity reported revenue of $1.17B for the fiscal year ended Dec 31, 2025, down 2.7% from the year before. That year, net income was -$167.10M with a net margin of -14.3%, operating cash flow was $331.20M and free cash flow was $273.50M. The quarter ended Sep 30, 2026 had revenue of $305.10M and net income of $49.30M.
Revenue and Margins
The operating margin was -3.8% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $908.30M, a compound annual rate of 2.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.17B | -2.7% | 39.5% | -3.8% | -14.3% |
| Dec 2024 | $1.20B | -1.3% | 38.7% | -3.5% | -35.9% |
| Dec 2023 | $1.22B | -27.1% | 36.6% | 16.5% | -0.4% |
| Dec 2022 | $1.67B | +19.9% | 34.2% | 19.4% | 12.7% |
| Dec 2021 | $1.39B | +14.4% | 36.9% | 20.9% | 8.5% |
| Dec 2020 | $1.22B | -5.9% | 38.3% | 22.5% | 14.9% |
| Dec 2019 | $1.29B | +14.1% | 37.3% | 20.9% | 14.2% |
| Dec 2018 | $1.13B | +16.6% | 36.8% | 22.3% | 16.0% |
| Dec 2017 | $972.40M | +7.1% | 33.8% | 19.7% | 14.9% |
| Dec 2016 | $908.30M | N/A | 30.2% | 11.2% | 4.9% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income rose 13.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.17B | $1.20B | $1.22B | $1.67B | $1.39B | $1.22B | $1.29B | $1.13B | $972.40M | $908.30M |
| Cost of revenue | $706.10M | $735.30M | $770.50M | $1.10B | $878.70M | $750.60M | $810.90M | $716.80M | $643.40M | $633.90M |
| Gross profit | $461.50M | $464.80M | $445.00M | $570.10M | $512.80M | $465.50M | $482.00M | $416.80M | $329.00M | $274.40M |
| Research and development | $28.40M | $24.50M | $25.40M | $30.30M | $26.30M | $22.60M | $19.70M | $21.50M | $19.80M | $17.60M |
| Operating income | -$44.00M | -$42.50M | $200.80M | $323.90M | $290.40M | $273.20M | $270.50M | $252.60M | $191.10M | $101.70M |
| Net income | -$167.10M | -$430.30M | -$5.40M | $211.60M | $118.10M | $181.40M | $183.70M | $181.80M | $145.20M | $44.40M |
| EBITDA | $37.40M | $57.90M | $339.80M | $432.70M | $320.40M | $370.50M | $359.80M | $301.60M | $237.10M | $137.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $305.10M | $314.10M | $258.00M | $185.40M | $333.10M | $331.50M | $247.90M | $135.60M | $333.80M | $390.60M | $340.10M | -$104.90M |
| Gross profit | $132.80M | $139.00M | $116.40M | $76.30M | $133.90M | $127.80M | $111.90M | $110.30M | $131.60M | $123.20M | $99.70M | $32.60M |
| Operating income | $86.20M | $60.10M | $68.50M | -$56.30M | $81.80M | -$113.80M | $57.00M | $178.10M | $84.30M | -$287.50M | -$17.40M | $9.50M |
| Net income | $49.30M | $35.30M | $59.80M | -$84.60M | $43.50M | -$146.50M | $20.50M | $16.60M | -$107.20M | -$283.70M | -$56.00M | -$116.80M |
Balance Sheet
As of Dec 2025, total debt of $1.21B exceeded cash and equivalents by $1.13B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.65B | $2.02B | $2.62B | $2.74B | $2.47B | $2.33B | $2.14B | $1.32B | $929.60M | $832.80M |
| Current assets | $454.20M | $493.20M | $658.60M | $683.30M | $724.90M | $628.70M | $463.20M | $422.70M | $368.70M | $295.20M |
| Cash and equivalents | $78.10M | $68.00M | $95.90M | $76.70M | $275.40M | $257.70M | $56.50M | $77.50M | $87.90M | $30.50M |
| Total liabilities | $1.62B | $1.83B | $1.99B | $2.04B | $1.80B | $1.69B | $1.61B | $976.50M | $651.70M | $698.20M |
| Short-term debt | $47.10M | $61.30M | $84.40M | $900.00K | $19.60M | $26.00M | $22.50M | $11.20M | $9.40M | $7.50M |
| Long-term debt | $1.16B | $1.34B | $1.38B | $1.47B | $1.25B | $1.27B | $1.23B | $741.20M | $444.00M | $481.30M |
| Shareholder equity | $29.70M | $195.20M | $631.40M | $698.30M | $673.80M | $642.10M | $530.80M | $338.70M | $263.90M | $127.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.50B | $1.54B | $1.65B | $1.65B | $1.83B | $1.88B | $2.06B | $2.02B | $2.21B | $2.28B | $2.57B | $2.62B |
| Total liabilities | $1.44B | $1.49B | $1.61B | $1.62B | $1.70B | $1.76B | $1.82B | $1.83B | $2.00B | $1.99B | $2.00B | $1.99B |
| Cash and equivalents | $85.40M | $97.40M | $95.40M | $78.10M | $83.40M | $76.90M | $71.50M | $68.00M | $135.50M | $107.40M | $88.50M | $95.90M |
| Shareholder equity | $63.00M | $46.90M | $38.90M | $29.70M | $138.10M | $120.70M | $234.60M | $195.20M | $214.50M | $284.80M | $568.20M | $631.40M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 82.6% of operating cash flow. Share repurchases came to 20.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $331.20M | $128.60M | $205.10M | $313.40M | $293.30M | $352.40M | $275.70M | $252.00M | $174.30M | $127.90M |
| Capital expenditures | $57.70M | $77.60M | $109.80M | $142.50M | $103.80M | $82.10M | $114.80M | $93.90M | $52.60M | $56.70M |
| Free cash flow | $273.50M | $51.00M | $95.30M | $170.90M | $189.50M | $270.30M | $160.90M | $158.10M | $121.70M | $71.20M |
| Dividends paid | N/A | N/A | N/A | $4.10M | $4.70M | $3.60M | $4.10M | $95.30M | $12.30M | $453.90M |
| Share repurchases | $56.30M | $0 | $92.10M | $145.20M | $109.40M | $88.00M | $6.40M | $47.40M | $6.60M | $0 |
| Investing cash flow | -$57.50M | -$79.50M | -$77.30M | -$551.90M | -$138.60M | -$110.60M | -$658.30M | -$414.40M | -$58.60M | -$126.40M |
| Financing cash flow | -$252.20M | -$70.20M | -$99.90M | $48.10M | -$133.10M | -$50.20M | $369.20M | $153.70M | -$57.80M | -$3.40M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $99.20M | -$13.80M | -$2.00M | $97.10M | $129.70M | $79.00M | $25.40M | $64.50M | $46.50M | $29.70M | -$12.10M | $46.20M |
| Capital expenditures | $13.70M | $10.30M | $10.30M | $23.60M | $11.90M | $12.20M | $10.00M | $24.90M | $18.00M | $18.10M | $16.60M | $29.20M |
| Free cash flow | $85.50M | -$24.10M | -$12.30M | $73.50M | $117.80M | $66.80M | $15.40M | $39.60M | $28.50M | $11.60M | -$28.70M | $17.00M |
Frequently Asked Questions About NGVT
What is Ingevity's annual revenue?
Ingevity reported revenue of $1.17B for the fiscal year ended Dec 31, 2025.
How fast is Ingevity's revenue growing?
Revenue was down 2.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -11.2%.
Is Ingevity profitable?
No. Ingevity reported net income of -$167.10M for the fiscal year ended Dec 31, 2025, with a net margin of -14.3%.
How much free cash flow does NGVT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $331.20M minus capital expenditures of $57.70M produced free cash flow of $273.50M.
How much debt does Ingevity have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.16B, short-term debt of $47.10M and cash and equivalents of $78.10M.
NGVT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors